Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

ost common adverse events among patients receiving Viread with other antiretroviral agents in a pivotal clinical study (Study 903) were mild to moderate gastrointestinal events and dizziness. Moderate to severe adverse events occurring in more than 5 percent of patients receiving Viread included rash (rash, pruritis, maculopapular rash, urticaria, vesiculobullous rash and pustular rash), headache, pain, diarrhea, depression, back pain, fever, nausea, abdominal pain, asthenia (weakness) and anxiety. In another pivotal study (Study 907), less than 1 percent of patients discontinued participation because of gastrointestinal events.

It is important for patients to be aware that anti-HIV medicines including Viread do not cure HIV infection or AIDS and do not reduce the risk of transmitting HIV to others. Full prescribing information is available at www.GileadHIV.com.

The parent compound of Viread was discovered through a collaborative research effort between Dr. Antonin Holy, Institute for Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic (IOCB) in Prague and Dr. Erik DeClercq, Rega Institute for Medical Research, Katholic University in Leuven, Belgium.

About Hepsera

Hepsera, a nucleotide analogue for the treatment of chronic hepatitis B, works by inhibiting HBV DNA polymerase, an enzyme involved in the replication of the virus in the body.

In the United States, Hepsera is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

The adverse reactions considered at least possibly related to treatment reported in 3 percent or greater of patients in the first 48 weeks in Hepsera pivotal clinical studies were asthenia, headache, abdominal pain, nausea, flatulence, diarrhea and dyspepsia.
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:5/29/2015)... , May 29, 2015 Eli Lilly and ... Sachs 36th Annual Global Healthcare Conference on Tuesday, June ... and president, Elanco Animal Health, will participate in a ... A live audio webcast will be available ... website at http://investor.lilly.com/events.cfm . A replay of the ...
(Date:5/29/2015)... SPARTANBURG, South Carolina , May 29, 2015 /PRNewswire/ ... Health have announced a collaboration designed to provide therapeutic ... the majority of cancer patients living in U.S. communities. ... Molecular Health to harness the power of big data ... of thousands of patients to enable ,accrual on demand, ...
(Date:5/29/2015)... Research and Markets ( ... "Surgical/Operating Microscopes Market by Application & End ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... poised to reach $806.6 million by 2020 from ... 12.3% from 2015 to 2020. , ,Major factors ...
Breaking Medicine Technology:Lilly to Participate in Goldman Sachs Global Healthcare Conference 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 4Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2
... 12 A new software technology is helping to ... by electronically identifying the sperm, eggs, resulting embryos and ... (IVF) treatment cycles. Using non-invasive Radio Frequency Identification (RFID), ... embryos during the course of treatment. If the wrong ...
... ABBOTT PARK, Ill., Nov. 12 Nearly one in three ... and nearly 34 million have low HDL "good" cholesterol levels. ... and trigs, Abbott has launched two Web sites: ... "Unhealthy high triglyceride and low HDL levels are factors that ...
Cached Medicine Technology:New Technology Reduces Risk of IVF Laboratory Mistakes by Electronically Identifying Sperm, Eggs and Other Materials for Each Patient 2New Technology Reduces Risk of IVF Laboratory Mistakes by Electronically Identifying Sperm, Eggs and Other Materials for Each Patient 3New Web Sites Educate About Triglycerides and HDL Cholesterol 2
(Date:5/30/2015)... May 30, 2015 At 73 years old, ... vibrant health , which she attributes to a lifetime ... of good nutrition with the release of her new book ... Xlibris AU). , “Cook for Health and Longevity” features a ... and mostly organic food . It is designed to ...
(Date:5/30/2015)... 2015 Cyclist Barry Haarde will ... the World 2015: Piles of Miles” near San ... about hemophilia and encourage individuals to support needy ... Save One Life supports nearly 1,200 impoverished children ... through direct sponsorships, scholarships and micro-enterprise grants. Hemophilia ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 San ... that she is offering a free analysis and consultation ... offer coincides with Disability Awareness Month, which was created ... members across the United States such as Polk recognize ... raise awareness about the possibility of disability, as well ...
(Date:5/30/2015)... The iconic American actor, and host ... a new segment on Medical Malpractice. This segment of ... in the health care field. , According to the ... malpractice suits were filed, roughly only 20% of them ... of court, while the remaining 30% were tossed out. ...
(Date:5/30/2015)... May 30, 2015 “ Milli the Snail ... AppWatch, which takes a look at the latest and coolest ... Toohey, the host of AppWatch and technology expert, conducted the ... aesthetic game that engages and educates children. , Interactive mobile ... not all the content and games they are playing are ...
Breaking Medicine News(10 mins):Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2
... WILMINGTON, Delaware, September 2 According to a ... by MarketsandMarkets,( http://www.marketsandmarkets.com ), the global emerging lighting technologies,market ... recording an,estimated CAGR of 7.9% from 2009 to 2014. ... 39% of the total revenues. , ...
... , , SAN JOSE, Calif., Sept. ... company, today announced that its IsoFlow (TM) infusion ... Drug Administration (FDA) for the direct delivery of medications into highly ... treatment of cancer. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090902/SF69552 ) ...
... What you need to know about vaccinations for swine flu, ... fall, Americans will face a double challenge in getting shots ... and the seasonal variety. , "Two different vaccines are ... Hay, an assistant professor of medicine at the University of ...
... , , , LA JOLLA, ... today announced that Dr. Juliet Singh, President and Chief Executive Officer ... Partners Healthcare Conference in Boston, MA on Wednesday, September 9, 2009 ... can access a live audio webcast via the Internet by visiting ...
... , , WASHINGTON, Sept. 2 Danaher ... has signed a definitive agreement with MDS Inc. (TSX: MDS; ... division of MDS, which includes a 50% ownership position in ... business, and a 100% ownership position in the former Molecular ...
... , , MOUNTAIN VIEW, Calif., Sept. ... it will participate in the following events in September: , , ... Friday, September 11, at 10:20 a.m. ET in Boston, ... 13, in Philadelphia, Late-Breaking oral platform presentation on Saturday, September ...
Cached Medicine News:Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 2Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 4Health News:Keep Your Flu Shots Straight This Fall 2Health News:Keep Your Flu Shots Straight This Fall 3Health News:Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 3Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 4Health News:MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: